Fentanyl, Xylazine, and the New Face of Drug Misuse: What Every Prescriber Should Know About Modern Toxicology Testing

By Ryah Luevano

Updated: July 9th, 2026
Published: July 9th, 2026

The drugs showing up in patient specimens today look very different from the drugs that shaped toxicology protocols a decade ago. Fentanyl has displaced heroin as the dominant illicit opioid in most of the country, and a veterinary sedative called xylazine — often nicknamed “tranq” — is now turning up mixed into fentanyl supplies with increasing frequency. For prescribers who depend on drug testing to monitor patients on controlled substances or evaluate suspected misuse, this shift changes what a truly “comprehensive” panel needs to cover.

The Drug Supply Has Changed Faster Than Many Testing Panels

Many standard drug-screening panels were built around a previous generation of substances: natural opiates, benzodiazepines, amphetamines, and a handful of illicit drugs. Basic immunoassay screens, in particular, are designed to detect broad drug classes and were never built to reliably catch newer synthetic opioids or novel adulterants. A patient can screen “clean” on a routine panel while still having fentanyl, a fentanyl analog, or xylazine in their system — simply because the panel wasn’t designed to look for it.

What Is Xylazine, and Why Does It Matter Clinically?

Xylazine is a non-opioid sedative approved for veterinary use, not for humans. It has increasingly appeared as a cutting agent in the illicit opioid supply, typically combined with fentanyl. That combination matters for two clinical reasons. First, because xylazine is not an opioid, naloxone does not reverse its sedative or respiratory-depressant effects, which complicates overdose response even after an opioid antagonist has been given. Second, xylazine exposure has been associated with severe, slow-healing skin wounds and ulcers, including at sites unrelated to injection. A patient presenting with unexplained wounds or unusually prolonged sedation may be a candidate for xylazine-specific testing, not just a standard opioid panel.

Why Immunoassay Screening Alone Often Isn’t Enough

Point-of-care immunoassay cups are inexpensive and fast, which makes them a useful first-line tool. But they carry real limitations: they can produce false negatives for compounds they weren’t designed to detect (including many synthetic opioids and specialty fentanyls), and they can produce false positives due to cross-reactivity with other compounds. Confirmatory testing with LC-MS/MS (liquid chromatography–tandem mass spectrometry) resolves both problems by identifying the exact compound present and its concentration, rather than just flagging a drug class.

What a Modern Toxicology Panel Should Include

When evaluating whether a testing panel still matches today’s drug landscape, look for coverage of:

• Fentanyl and its metabolite, norfentanyl
• Specialty fentanyl analogs (e.g., acetyl fentanyl, butyryl fentanyl, sufentanil)
• Xylazine
• A full opioid and opioid-analog menu, not just natural opiates
• Common illicit stimulants and their metabolites
• The prescribed medication classes relevant to consistency monitoring (e.g., benzodiazepines, antidepressants, antipsychotics, skeletal muscle relaxants)

How Southwest Labs Approaches Comprehensive Toxicology Testing

Southwest Labs runs LC-MS/MS confirmation testing across an 82+ analyte urine menu that includes specialty fentanyls and xylazine. Every result comes back on a color-coded, one-page report that flags results as consistent, inconsistent, or indicative of illicit or non-prescribed substances — so the clinically relevant information is visible at a glance rather than buried in a data table. Reports also include specimen validity testing (creatinine, oxidants, pH, and specific gravity) to flag dilution or tampering, and results are typically available within 24 to 72 hours.

What This Means for Your Practice

• Order a comprehensive confirmatory panel rather than relying on immunoassay screening alone, especially for patients on chronic opioid therapy or with a history of substance use.
• Remember that a “clean” screen doesn’t rule out xylazine or newer synthetic compounds unless the panel specifically tests for them.
• Use results as the start of a clinical conversation with the patient, not only as a compliance checkbox.
• Work with a lab that actively updates its test menu as the drug supply continues to evolve.

Southwest Labs is a locally owned, CAP- and CLIA-accredited reference laboratory based in Albuquerque, serving providers throughout New Mexico with toxicology and infectious disease testing. To review our current toxicology test menu or get started sending samples, contact our team at Info@southwestlab.com or (505) 609-LABS.